Lynx1 Capital Management LP bought a new stake in shares of Vor Biopharma Inc. (NYSE:VOR - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 637,218 shares of the company's stock, valued at approximately $707,000. Vor Biopharma comprises approximately 0.3% of Lynx1 Capital Management LP's portfolio, making the stock its 15th largest holding. Lynx1 Capital Management LP owned approximately 0.93% of Vor Biopharma at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Vor Biopharma in the fourth quarter valued at about $33,000. XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the fourth quarter worth $80,000. Finally, Virtu Financial LLC acquired a new position in Vor Biopharma in the 4th quarter worth $60,000. Institutional investors and hedge funds own 97.29% of the company's stock.
Wall Street Analysts Forecast Growth
VOR has been the subject of a number of recent research reports. Stifel Nicolaus reduced their price target on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Wedbush restated an "outperform" rating and issued a $7.00 price objective on shares of Vor Biopharma in a report on Thursday, March 20th. HC Wainwright lowered their price target on Vor Biopharma from $17.50 to $13.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Finally, Oppenheimer reissued an "outperform" rating and issued a $8.00 target price on shares of Vor Biopharma in a research note on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma currently has an average rating of "Buy" and a consensus price target of $8.86.
Check Out Our Latest Report on VOR
Vor Biopharma Stock Up 3.3 %
Shares of Vor Biopharma stock traded up $0.02 on Friday, hitting $0.68. The stock had a trading volume of 112,117 shares, compared to its average volume of 585,958. The stock has a market cap of $85.27 million, a price-to-earnings ratio of -0.41 and a beta of -0.21. The business's 50 day moving average is $0.78 and its two-hundred day moving average is $0.98. Vor Biopharma Inc. has a twelve month low of $0.49 and a twelve month high of $1.87.
Vor Biopharma Profile
(
Free Report)
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Further Reading
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
